Biotech/Life Sciences

8:30

Networking and expo

Meet and greet with fellow attendees visiting the MaRS Impact Health expo.

Meet and greet with fellow attendees visiting the MaRS Impact Health expo.

9:30

Welcome and opening remarks

What to look forward to on day one of MaRS Impact Health.

What to look forward to on day one of MaRS Impact Health.

9:40

Vital signs: Biotech

Checking the pulse of innovation in biotech and life sciences.

Checking the pulse of innovation in biotech and life sciences.

9:45

Fireside with Jessica Chutter, chair of biotechnology investment banking at Morgan Stanley

A conversation on ensuring life science startups not just survive — but thrive. Is now a...

A conversation on ensuring life science startups not just survive — but thrive. Is now a good time to start building a venture? What should companies do to raise capital? How will today’s funding environment impact early-stage ventures? This session seeks to answer these questions and more, highlighting what’s new vs. what’s tried and true.

11:15

Break + structured networking sessions

11:45

Commercializing the next generation of cell-based therapeutics

Cell and gene therapy innovation is quickly moving from early-stage development to commercialization, and one of...

Cell and gene therapy innovation is quickly moving from early-stage development to commercialization, and one of the biggest shifts to this new era of pharma centres around the supply chain. What will payment flow look like? How will end-end closed loop affect scaling? How will ventures secure partners to get therapeutics to a patient’s bedside? Will pharma shift quickly, or does this new model need a playbook? How can Canada become a global leader to get innovative new therapeutics to patients?

12:25

Lunch and networking

1:00

Bridging the divide between breakthrough science and commercial impact

Hear from leading innovators, investors and professionals working in the life sciences sector on the unique...

Hear from leading innovators, investors and professionals working in the life sciences sector on the unique collaborations they’ve established and lessons they’ve learned while scaling successful biotech companies.

2:15

Break + structured networking sessions

2:45

Perspectives from the pharmaceutical industry: Oncology outlook

This session explores the shifting biotech landscape through the eyes of two large pharmaceutical companies. What...

This session explores the shifting biotech landscape through the eyes of two large pharmaceutical companies. What areas in oncology is pharma focused on to fill the R&D pipeline and upcoming patent cliff? How will companies tackle the challenges of complex medicines? What are current pharma priorities and how should ventures position themselves?

3:15

Decentralization of clinical trials

A strategy born out of necessity during the pandemic, decentralized clinical trials (DCT) are becoming the...

A strategy born out of necessity during the pandemic, decentralized clinical trials (DCT) are becoming the new norm. DCT can reduce clinical trial timelines, patient recruitment and increase retention rates. This session looks at the impact of devices like wearables, sensors and smartphone apps, as well as other strategies that create more inclusive and reliable studies that ensure patient safety.

4:00

Mind the gaps

This session explores opportunities to accelerate commercial pathways for life sciences companies by digitizing supply chains,...

This session explores opportunities to accelerate commercial pathways for life sciences companies by digitizing supply chains, regulatory pathways, IP management, portfolio optimization and medical education. Meet the ventures filling these gaps right now.

4:40

Closing remarks from Daniel Kraft – Exponential healthcare: What's now, near and next

Medical futurist, physician-scientist, entrepreneur and investor Daniel Kraft will explore the latest advances in health innovation...

Medical futurist, physician-scientist, entrepreneur and investor Daniel Kraft will explore the latest advances in health innovation and what implications for the future of health and biomedicine. Daniel is a general partner at Continuum Health Ventures, an early stage health tech fund, and he chairs NextMed Health. He will share his insights on emerging technologies and advice to entrepreneurs working to build transformative healthcare ventures.

Devices and Digital Health

8:30

Networking and expo

Meet and greet with fellow attendees visiting the MaRS Impact Health expo.

Meet and greet with fellow attendees visiting the MaRS Impact Health expo.

9:30

Welcome and opening remarks

What to look forward to on day two of MaRS Impact Health.

What to look forward to on day two of MaRS Impact Health.

9:35

Vital signs: Digital health

Checking the pulse of innovation in the digital health sector.

Checking the pulse of innovation in the digital health sector.

9:40

Building a Canadian AI health ecosystem

The July 2020 CIFAR Task Force Report proposed several initiatives to support AI in healthcare in...

The July 2020 CIFAR Task Force Report proposed several initiatives to support AI in healthcare in Canada. Initiatives include enabling responsible access to data allowing for privacy and security, accelerating the development of AI in healthcare and an initiative to promote adoption and procurement, encouraging all jurisdictions of government to align their strategy with relevant stakeholders. Learn more about what needs to happen to promote venture growth in this area.

11:10

Break + structured networking sessions

11:30

Music as medicine

A surprising intervention, music is increasingly being applied as treatment to help with a variety of...

A surprising intervention, music is increasingly being applied as treatment to help with a variety of conditions. This session will delve into how music can be a source of health and healing.

12:00

Lunch and networking

Cross sector pivots: Healthcare and mining

In today’s challenging economic climate, startups are eyeing other industries for new growth and expansion opportunities....

In today’s challenging economic climate, startups are eyeing other industries for new growth and expansion opportunities. These unexpected alliances and cross sector pivots are occurring across a range of industries with ventures branching out to fill gaps in unexpected places. For example, hear from Ibraheem Khan of Smarter Alloys on how his company applies its shape memory alloys to medical, automotive, and mining industries. When does it make sense for entrepreneurs to be industry agnostic and what tactics help when seeking opportunities in new fields? This session, moderated by Charles Nyabeze of Canada’s Mining Innovation Commercialization Accelerator, will feature several entrepreneurs who are collaborating across healthcare and mining, exploring how cross sector pivots and alliances happen and tactics for bridging innovation gaps across industries.

12:30

Vital signs: Devices

Checking the pulse of innovation in the medical device sector.

Checking the pulse of innovation in the medical device sector.

12:35

To regulate or not? Tech for cognitive function

Cognitive disorders and anxiety are often treated using pharmaceuticals and therapy techniques, but several devices are...

Cognitive disorders and anxiety are often treated using pharmaceuticals and therapy techniques, but several devices are ready to help. Hear from ventures using technologies like wearables and infrared light to boost cognition and memory and regulate mood.

2:15

Break + structured networking sessions

2:30

ChatGPT, machine learning and generative AI in healthcare

Healthcare is often characterized by multimodal data sets like text, visual, audio and genomics, but are...

Healthcare is often characterized by multimodal data sets like text, visual, audio and genomics, but are we actually close to using AI to provide a comprehensive view into personalized medicine? We take a closer look at what still needs to be done, and the opportunities and gaps that need to be filled.

3:00

The future of diagnostic devices: A delicate balance

Neural networks are enabling dramatic advances in disease diagnosis. But how do we balance product performance...

Neural networks are enabling dramatic advances in disease diagnosis. But how do we balance product performance with patient safety and access?

3:40

Opportunities in women's health

For decades, women have been vastly underrepresented in medical research and trials. That’s starting to change,...

For decades, women have been vastly underrepresented in medical research and trials. That’s starting to change, but many of the protocols for diagnosing and treating patients are based on what works for men. And issues facing women specifically receive far less attention than those affecting only men — five times more money goes to erectile dysfunction research than studies on premenstrual syndrome. This conversation looks at ongoing gaps and the opportunities to improve areas of women’s health that have long been ignored.

4:20

Women’s health innovators: Menstruation to menopause and beyond

Hear from several FemTech innovators on the impact of their digital health and software solutions targeting...

Hear from several FemTech innovators on the impact of their digital health and software solutions targeting women’s health and related areas.

5:00

Closing remarks from Brigitte Nolet of Roche Canada Pharma

5:30

Closing reception and FemTech showcase

Join us for a closing reception as we wrap up the final day of MaRS Impact...

Join us for a closing reception as we wrap up the final day of MaRS Impact Health. Focused on celebrating and showcasing innovators working in women’s health, this reception also provides the chance to connect and mingle with fellow attendees and speakers from the event.